

Optimal Control Analysis of An Age-Structured Malaria Model Incorporating Children Under Five Years and Pregnant Women

Abstract

In this article, we apply the optimal control theory to a new age-structured malaria model with three infectious compartments for people under five years, over five years and pregnant women. The model is formulated for malaria endemic areas in the world and the following malaria control strategies ITN, IRS, Chemoprophylaxis and Improved Clinical Treatment were examined and analysed on the mode. The Cost-effectiveness Analysis points out that more attention should be given Insecticide -Treated bed nets (ITNs) in order to eliminate the malaria disease globally because the female Anopheles mosquitoes need human blood to lay their eggs. The expression for the effective reproduction number (R_e) has been derived by using the next-generation method. The impact of the controls on the R_e was studied and it came out that all the four controls have a positive impact such that the ITNs can reduce R_e to zero as the value of ITNs approaches one. Pontryagin's Maximum Principle was applied to analyse the optimal control model theoretically and the optimality system was solved numerically through an iterative scheme.

The optimal plots (Fig.4-8) reveal that best control strategies for malaria elimination is the combination of ITN, Chemoprophylaxis and Improved Clinical Treatment. However, the Cost-effectiveness Analysis points out that ITN is economically best solution for fighting malaria in poor malaria endemic areas.

Keywords: Insecticide Treated bed nets (ITNs), Indoor Residual Spraying (IRS), Chemoprophylaxis, Improved Clinical Treatment, effective reproduction number.

1.1 INTRODUCTION

Optimal Control Theory (OCT) is a powerful mathematical tool which is used in making fruitful decisions in dynamical systems [6, 9]. It has also been applied in disease modelling [8], however, not much has been done in the area of malaria modelling, Even the few applications of the theory to existing malaria modelling do not include models having separate compartments for children under 5years and pregnant women [1, 2, 3, 4,]. The technique behind applying Optimal Control Theory to malaria modelling is to minimise the infected humans and vector population while maximizing the recovered human population using limited resources available [9]. The technique for analyzing disease models when one is applying Optimal Control Theory comes from the Pontryagin Maximum Principle (PMP). PMP is a classical result from optimal control theory which provides a necessary condition that must be satisfied by an optimal solution [8, 10]. We extend the existing malaria models on the time-optimal control of the SI epidemic model with compartments for children under five years and pregnant women. The control strategies to be incorporated in our model are Insecticide Treated bed nets (ITNs), Indoor Residual Spraying (IRS), Chemoprophylaxis and Improved Antimalarial drugs. Stability analysis has carried out on the model in this article in a previous article entitled "Analysis of an Age-Structured Malaria

42 Model Incorporating Infants and Pregnant Women” [31]. Sensitivity analysis in the previous
43 article proved that malaria can be controlled or eliminated if the following parameters such as
44 biting rates, recruitment rate and density-dependent natural mortality rate for mosquitoes and
45 clinical recovery rates for humans are controlled. Therefore, the focus of this article is to apply
46 optimal control theory to the said new model.

47 48 **1.2 PREVIOUS WORK**

49 Makinde and Okosun, [15] established the optimal strategies for malaria control with infected
50 immigrants. Also, Okosun, [16], Makinde and Okosun, [15], and Okosun et. al., [3] applied
51 optimal control theory to a continuous malaria model that includes treatment and vaccination
52 with waning immunity to study the impact of possible vaccination with treatment strategies in
53 controlling the spread of malaria. Silva and Torres [17] presented an optimal control approach to
54 malaria prevention via ITNs in which supervision control was introduced representing
55 information, education, communication (IEC) campaigns for improving the ITN usage. The
56 optimal control problem was developed and solved with the aim of minimizing the number of
57 infected humans while keeping the cost low. The numerical results showed the effectiveness of
58 the optimal control interventions. Only one prevention strategy, that is, ITN, was
59 investigated. Furthermore, Rafikov et al., [18] formulated a continuous model for malaria vector
60 control with the aim of studying how genetically modified mosquitoes should be introduced in
61 the environment using optimal control problem strategies.

62 Okosun et al., [3] showed that a possible vaccination combined with an effective treatment
63 regime would reduce the spread of the disease. Their research based on the combined
64 vaccination and treatment strategy. Optimal control strategy for Plasmodium vivax malaria
65 transmission in Korea was investigated using a deterministic system of differential equations.
66 This work suggested that if the cost of reducing the reproduction rate of the mosquito population
67 is more than that of prevention measures to minimize mosquito-human contacts, the control of
68 mosquito-human contacts needs to be taken for a longer period of time, comparing the other
69 situations [14]. Magombedze et al., [19] studied optimal control of malaria chemotherapy in
70 which an intra-host mathematical model of malaria that describes the interaction of the immune
71 system with the blood stage malaria merozoites was done. The model was modified by
72 incorporating the effects of malaria drugs that target blood stage parasites. The optimal control
73 represented percentage effects of the chemotherapy of chloroquine in combination with
74 chlorpheniramine on the reproduction of merozoites in erythrocytes. Their results indicated that
75 highly toxic drugs and small dosage sizes have the potential of improving the quality of life and
76 reduce economic costs of therapy.

77 Mwamtobe in his Ph.D. thesis applied optimal control theory to study optimal intervention
78 strategies for malaria epidemic in Karonga district in Malawi. Prevention strategies such
79 as insecticide treated bed-nets (ITNs) and indoor residual spraying (IRS) and treatment of
80 infected individuals were the control strategies considered in the study. Analysis of the model
81 suggested that effective control or eradication of malaria can be achieved by the combination of
82 protection and treatment measures. The work also suggested that making control strategies
83 readily available to both populations can play an important role in reducing or eradicating

84 malaria disease in Karonga District or in the entire Malawi nation. His work finally
85 recommended that a model with children under five years and pregnant women could shed more
86 light on which intervention strategy to prioritize to the specific groups [1]. Otieno et al [5] study
87 transmission dynamics and optimal control of malaria in Kenya. Their model use SEIRS type for
88 the human population with temporary immunity after recovery and the mosquito population was
89 described by the SEI model. The susceptible humans consist of children under the age of five
90 and pregnant women. The following control strategies were considered in this model: (i) the use
91 of treated bed nets, (ii) treatment of infective humans, (iii) spray of insecticides and (iv)
92 treatment to protect pregnant women and their newborn children: intermittent preventive
93 treatment for pregnant women (IPTp). The work suggested that the optimal control strategy for
94 malaria control in endemic areas is the combined use of treatment and IRS; in epidemic-prone
95 areas, it is the use of treatment and IRS; in seasonal areas, it is the use of treatment, and in low -
96 risk areas, is the use of ITNs and treatment. The work finally concluded that following these
97 strategies can effectively reduce the spread of malaria disease in different malaria transmission
98 settings in Kenya.

99

100 1.3 MODEL DESCRIPTION AND FORMULATION

101 The model proposed in this paper is an Age-Structured Malaria model having separate Infectious
102 Compartments for people under 5 years, over 5 years, and Pregnant women. Two populations,
103 that is, humans and adult female Anopheles mosquitoes are considered in the model (1). The
104 human population is partition into susceptible S_H , infected humans under 5years I_I , infected
105 humans over 5years I_A and infected pregnant women I_P . The mosquito population is also
106 divided into

107 Susceptible S_M and infected mosquitoes. I_M . The total population sizes at time t for
108 humans and mosquitoes are denoted by $N_H(t)$ and $N_M(t)$ respectively. We employ the SIS
109 type model for humans to describe the disease with malaria acquired immunity for those over
110 5years as long as they continue to live in malaria endemic areas and SI model for mosquitoes
111 since they do not recovery from the parasite infection. We incorporate four time-dependent
112 control measures simultaneously: (1) Insecticide Treated bed nets (ITNs), (2) Indoor Residual
113 Spraying (IRS), (3) Chemoprophylaxis and (4) Improved Antimalarial drugs. Detailed
114 description of the control functions is given in table 1. $S_H(t)$ represents the number of
115 individuals not yet infected with the malaria parasite at time t and $I_I(t)$, $I_A(t)$ and $I_P(t)$
116 represent those who are infected malaria parasites and are capable of transmitting the parasites to
117 susceptible mosquitoes. The susceptible humans consist of individual under 5 years, over 5years
118 and pregnant women. It is assumed every infected person recovers after a one-time period and
119 also through antimalarial drugs (clinical treatment). The immunity can be lost through
120 interruption of exposure, that is, if an immune person migrates to a non- endemic malaria region
121 where the exposure to the disease is not available, then he or she automatically loses their
122 immunity. The immunity can be restored through numerous years of repeated infections,
123 therefore a person living in malaria endemic area cannot lose his or her immunity as long as they
124 continue to stay in the area and the exposure to the disease continues. The advantage of those
125 with malaria immunity is that frequency of the malaria infections is reduced, which could delay
126 the frequency of malaria infections in those over 5years [20]. Newborns have malaria immunity
127 up to the first 3–6 months of their lives due to passive transfer of maternal antibodies through the
128 placenta. After these months, they are vulnerable to clinical malaria episodes until they develop
129 their own immunity [21]. People enter the human population through the susceptible (S_H)

130 compartment at per capita recruitment rate (Z_H). When the malaria infection begins in humans,
 131 the individuals under 5years move to I_I compartment, over 5years who are not pregnant move
 132 to I_A compartment and pregnant women move to I_P compartment. Those in infectious
 133 compartments I_I and I_A and I_P are clinically treated (that is, gametocytes are completely
 134 cleared) at the rates Λ_I , Λ_A and Λ_P respectively, before they return to S_H compartment for
 135 re-infection. . Also, the infectious individuals can exit the human population through disease-
 136 induced deaths at the rates (π_I) , (π_A) and (π_P) respectively. The infectious under 5years
 137 can join the infectious over 5years at the rate (ϕ) when they attain aged 5 and also infectious
 138 over 5years can join the infectious pregnant women compartment at the rate (Ω) when the
 139 become pregnant. It is assumed that infectious pregnant women cannot join the infectious over
 140 5years compartment since most infectious pregnant women are clinically treated before they give
 141 birth. Humans can also exit their population through density-dependent mortality rate (μ_H) in
 142 each compartment.

143 The adult female Anopheles mosquito becomes infectious when it bites gametocyte carriers (that
 144 is, infectious humans) and ingests the gametocytes. The mosquito in the S_M compartment
 145 becomes infectious and moves to the I_M compartment only when the malaria parasites becomes
 146 mature and moves to the mosquito's salivary glands and remains in the infectious status for life.
 147 The mosquito exits its population through density-dependent mortality at the rate (μ_M) or
 148 mortality due to insecticides but cannot die directly from the malaria parasite infection [22].
 149 Female mosquitoes enter their population through the susceptible compartment at per capita
 150 recruitment rate (Z_M). It is assumed that there is no immigration of infectious individuals in
 151 the human population.


152
 153 Table 1: Control functions

Control Functions	Description
u_1	It is a control variable which represents the fraction of individuals using the Insecticide Treated bed nets (ITNs). The impact of the control on the model is that, it will prevent the mosquitoes from biting the human population in sleeping areas and also reduce recruitment rate for mosquitoes, because the mosquitoes need blood to lay their eggs. In order to simplify the model, the force of infections are multiplied It by the factor $(1 - u_1(t))$, .which represents the failure rate of using ITNs [2]. It benefits the members of the human population equally or uniformly.
u_2	It is a control variable representing the fraction of mosquitoes killed by indoor residual spraying (IRS). The IRS will reduce the mosquito population by killing the mosquitoes, especially those that rest indoors after taken a blood meal (so called endophilic mosquitoes) [29]. The mosquito population is reduced by $-\beta u_2(t)S_M$ in susceptible population and $-\beta u_2(t)I_M$ in infectious population It benefits the members of the human population equally or uniformly, where β is the rate at which mosquitoes are killed by insecticides application.

u_3	It is a control variable which represents the fraction of people under 5years using Chemoprophylaxis. It will prevent the malaria parasite from developing and growing in the human body. Therefore, when one takes Chemoprophylaxis, he or she will not develop malaria infection during the period. In order to simplify the model, the infectious people under 5years population is decreased by $u_3(t)I_I$ and susceptible human population is increased by $u_3(t)I_I$
u_4	It is a control variable which represents the fraction of people over 5years using Chemoprophylaxis. The infectious people over 5years population is decreased by $u_4(t)I_A$ and susceptible human population is increased by $u_4(t)I_A$.
u_5	It is a control variable which represents the fraction of pregnant women population using Chemoprophylaxis. The infectious pregnant women population is decreased by $u_5(t)I_P$ and susceptible human population is increased by $u_5(t)I_P$.
u_6	It is a control variable which represents the effort to increase the current recovery rate for people under 5years through the use of improved Antimalarial drugs
u_7	It is a control variable which represents the effort to increase the current recovery rate for people over 5years through the use of improved Antimalarial drugs
u_8	It is a control variable which represents the effort to increase the current recovery rate for pregnant women through the use of improved Antimalarial drugs

154
155
156
157

The Flow Chart for malaria transmission dynamics without the four control strategies is given below as figure 1.



158
 159
 160
 161
 162
 163

The Flow Chart for malaria transmission dynamics with the four control strategies is given below as figure 2.




Figure 2: Flow Chart for the malaria transmission dynamics with the four control strategies

The flow chart demonstrates the interactions between human and mosquito populations and the movement of individuals from one compartment to another. The solid arrows show progression of individuals from one compartment to another and the dotted arrows show how the humans and mosquitoes interact and infect each other. Susceptible humans in S_H get infected when infectious mosquitoes from I_M bite them. They then progress to I_I , I_A and I_P when they are infectious. Humans in I_I , I_A and I_P move to S_H compartment for re-infection after clinical treatment. Susceptible mosquitoes in S_M get infected when they bite humans in I_I , I_A and I_P compartments and then move to I_M when they are infectious. Mosquitoes remain in I_M until they die through density-dependent mortality or insecticide (IRS). Humans exit their population through density-dependent mortality and disease-induced mortality. Mosquitoes enter their population at per capita recruitment rate and Humans enter through birth or immigration. Chemoprophylaxis and Improved Antimalarial drugs will reduce the number of humans in I_I , I_A and I_P compartments and increase the number of people in S_H compartment. IRS will reduce the mosquitoes in both S_M and I_M compartments and ITNs will also reduce the force of infections (α_I , α_A , α_P and α_M).

167 Detailed description of the parameters and their values of figure 1 are given in Table 2
 168 below.

169
 170

Table 2: The parameters for the model 1 [30]

Parameter	Value	Description
Z_H	414521	Recruitment for the human population. Dimension: Humans \times Time ⁻¹
Z_M	134267979835	Recruitment rate for mosquitoes. Dimensions: Time ⁻¹
μ_H	0.016	Density-dependent natural mortality rate for humans. Dimensions: Time ⁻¹
μ_M	0.058176	Density-dependent natural mortality rate for adult female Anopheles mosquitoes. Dimensions: Time ⁻¹
π_I	0.020605	Per capita disease-induced mortality rate for people under 5 years. Dimensions: Time ⁻¹
π_A	0.19113	Per capita disease-induced mortality rate for people over 5 years Dimensions: Time ⁻¹
π_P	0.49273	Per capita disease-induced mortality rate for pregnant women Dimensions: Time ⁻¹
Λ_I	0.11855	Clinical recovery rate for people under 5 years. Dimensions: Time ⁻¹
Λ_A	0.14348	Clinical recovery rate for people over 5 years. Dimensions: Time ⁻¹
Λ_P	0.14154	Clinical recovery rate for the pregnant women. Dimensions: Time ⁻¹
θ_{MH}	0.00016937	Fraction of bites that successfully infect humans
θ_{HM}	0.00454	Fraction of bites that successfully infect mosquitoes.
Φ_I	0.33575	Number of bites on people under 5 years per female mosquito per unit time. Dimensions: Time ⁻¹
Φ_A	0.98982	Number of bites on people over 5 years per female mosquito per unit time. Dimensions: Time ⁻¹
Φ_P	0.012704	Number of bites on pregnant women per female mosquito per unit time. Dimensions: Time ⁻¹
ϕ	0.10743	Rate of progression from I_I to I_A compartment. Dimensions: Humans \times Time ⁻¹
Ω	0.016744	Rate of progression from I_A to I_P compartment. Dimensions: Humans \times Time ⁻¹

171
 172
 173

1.4 MALARIA MODELS

174 Putting the assumptions and the ideas together, the malaria model without the four control is
 175 given by a system of six (6) differential equations as stated in (1) below.
 176

$$\left. \begin{aligned}
 \frac{dS_H}{dt} &= Z_H + \Lambda_I I_I + \Lambda_A I_A + \Lambda_P I_P - \alpha_I S_H - \alpha_A S_H - \alpha_P S_H - \mu_H S_H \\
 \frac{dI_I}{dt} &= \alpha_I S_H - \Lambda_I I_I - (\mu_H + \pi_I) I_I - \phi I_I \\
 \frac{dI_A}{dt} &= \alpha_A S_H + \phi I_I - (\mu_H + \pi_A) I_A - \Lambda_A I_A - \Omega I_A \\
 \frac{dI_P}{dt} &= \alpha_P S_H + \Omega I_A - (\mu_H + \pi_P) I_P - \Lambda_P I_P \\
 \frac{dS_M}{dt} &= Z_M - \alpha_M S_M - \mu_M S_M \\
 \frac{dI_M}{dt} &= \alpha_M S_M - \mu_M I_M
 \end{aligned} \right\} \dots \dots (1)$$

177
 178 The malaria model with the four controls is given below as (2)

$$\left. \begin{aligned}
 \frac{dS_H}{dt} &= Z_H + ((1 + u_6)\Lambda_I + u_3)I_I + ((1 + u_7)\Lambda_A + u_4)I_A + ((1 + u_8)\Lambda_P + u_5)I_P \\
 &\quad - (\mathbf{1} - \mathbf{u}_1)\alpha_I S_H - (\mathbf{1} - \mathbf{u}_1)\alpha_A S_H - (\mathbf{1} - \mathbf{u}_1)\alpha_P S_H - \mu_H S_H \\
 \frac{dI_I}{dt} &= (\mathbf{1} - \mathbf{u}_1)\alpha_I S_H - (\mu_H + \pi_I + u_3 + (1 + u_6)\Lambda_I + \phi)I_I \\
 \frac{dI_A}{dt} &= (\mathbf{1} - \mathbf{u}_1)\alpha_A S_H + \phi I_I - (\mu_H + \pi_A + u_4 + (1 + u_7)\Lambda_A + \Omega)I_A \\
 \frac{dI_P}{dt} &= (\mathbf{1} - \mathbf{u}_1)\alpha_P S_H + \Omega I_A - (\mu_H + \pi_P + u_5 + (1 + u_8)\Lambda_P)I_P \\
 \frac{dS_M}{dt} &= Z_M - (\mathbf{1} - \mathbf{u}_1)\alpha_M S_M - [\mu_M + \beta u_2]S_M \\
 \frac{dI_M}{dt} &= (\mathbf{1} - \mathbf{u}_1)\alpha_M S_M - [\mu_M + \beta u_2]I_M
 \end{aligned} \right\} \dots (2)$$

180
 181 Applying the definitions of the force of infections as stated in the model of Addawe and Lope
 182 [23] the force of infections for infants, adults and pregnant women are
 183

$$\alpha_I = \frac{\Phi_I \theta_{MH} I_M'}{N_H}, \quad \alpha_A = \frac{\Phi_A \theta_{MH} I_M}{N_H} \quad \text{and} \quad \alpha_P = \frac{\Phi_P \theta_{MH} I_M}{N_H} . \quad \dots \dots \dots (3)$$

184
 185 The force of infection for mosquitoes is

$$\alpha_M = \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P) \theta_{HM}}{N_H} . \quad \dots \dots \dots (4)$$

186 Substituting (3) and (4) into (2), leads to (5).
187

$$\left. \begin{aligned} \frac{dS_H}{dt} &= Z_H + ((1 + u_6)\Lambda_I + u_3)I_I + ((1 + u_7)\Lambda_A + u_4)I_A + ((1 + u_8)\Lambda_P + u_5)I_P \\ &\quad - \frac{(\Phi_I + \Phi_A + \Phi_P)(1 - \mathbf{u}_1)\theta_{MH}I_M S_H}{N_H} - \mu_H S_H \\ \frac{dI_I}{dt} &= \frac{\Phi_I(1 - \mathbf{u}_1)\theta_{MH}I_M S_H}{N_H} - (A_1 + u_3 + u_6\Lambda_I)I_I \\ \frac{dI_A}{dt} &= \frac{\Phi_A(1 - \mathbf{u}_1)\theta_{MH}I_M S_H}{N_H} + \phi I_I - (A_2 + u_4 + u_7\Lambda_A)I_A \\ \frac{dI_P}{dt} &= \frac{\Phi_P(1 - \mathbf{u}_1)\theta_{MH}I_M S_H}{N_H} + \Omega I_A - (A_3 + u_5 + u_8\Lambda_P)I_P \\ \frac{dS_M}{dt} &= Z_M - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(1 - \mathbf{u}_1)\theta_{HM} S_M}{N_H} - [\mu_M + \beta u_2] S_M \\ \frac{dI_M}{dt} &= \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(1 - \mathbf{u}_1)\theta_{HM} S_M}{N_H} - [\mu_M + \beta u_2] I_M \end{aligned} \right\} \dots (5)$$

where $A_1 = (\mu_H + \pi_I + \Lambda_I + \phi)$, $A_2 = (\mu_H + \pi_A + \Lambda_A + \Omega)$ and $A_3 = (\mu_H + \pi_P + \Lambda_P)$.

188 There initial state variables are $S_H(0) = 15475505$, $I_I(0) = 1303685$,
 $I_A(0) = 2045843$, $I_P(0) = 102834$, $S_M(0) = 246,498,646,800$ and
 $I_M(0) = 2,061,060,114,000$.

189 1.5 INVARIANT REGION

190
191 The invariant region is a region where solutions of the model (5) exist biologically [13].
192 Biological entities cannot be negative, therefore all the solutions of the model (5) are
193 positive for all time $t \geq 0$. [24]
194

195 The total population sizes N_H and N_M can be defined by $N_H = S_H + I_I + I_A + I_P$
196 and $N_M = S_M + I_M$.

197
198 In absence of the malaria disease, the differential equation for N_H is given as
199

$$\frac{dN_H}{dt} \leq Z_H - \mu_H N_H \quad \dots \dots \dots (6)$$

200 The differential equation for N_M is also given as

201

$$\frac{dN_M}{dt} < Z_M - [\mu_M + \beta u_2]N_M \dots \dots \dots (7)$$

202

203 **Lemma 1.** The model (5) has feasible solutions which are contained in the proper subset

$$\Psi = \Psi_H \times \Psi_M .$$

204

205 Proof

206 Let $(S_H , I_I , I_A , I_P , S_M , I_M) \in R_+^6$ be any solution of the system
 207 with non-negative initial conditions. Using (6)

208

$$\frac{dN_H}{dt} \leq Z_H - \mu_H N_H \implies \int d(N_H e^{\mu_H t}) \leq Z_H \int e^{\mu_H t} dt$$

209

$$N_H \leq \frac{Z_H}{\mu_H} + \left(N_{H0} - \frac{Z_H}{\mu_H} \right) e^{-\mu_H t} \dots \dots \dots (8)$$

210

211 Therefore, as $t \rightarrow \infty$, the human population N_H approaches $\frac{Z_H}{\mu_H}$ and it follows that [13]
 212

213

$$\lim_{t \rightarrow \infty} \sup N_H(t) \leq \frac{Z_H}{\mu_H} \text{ and } \lim_{t \rightarrow \infty} \sup N_M(t) \leq \frac{Z_M}{[\mu_M + \beta u_2]} .$$

214

215

216 Therefore, the feasible solution set for the model (5) is given by

217

$$\Psi = \left\{ \begin{array}{l} (S_H , I_I , I_A , I_P , S_M , I_M) \in R_+^6 : (S_H , S_M) > 0 \\ (I_I , I_A , I_P , I_M) \geq 0 ; S_H + I_I + I_A + I_P \leq \frac{Z_H}{\mu_H} ; S_M + I_M \leq \frac{Z_M}{[\mu_M + \beta u_2]} \end{array} \right\}$$

218

219

220 1. 6 DISEASE-FREE EQUILIBRIUM POINT

221

222 **Definition 1** A disease-free equilibrium point (DFE) is a steady state solution of the model for
 223 which there is no malaria disease in the population. It is obtained by setting (5) to zero [13].
 224

224

225 The disease-free equilibrium E_0 of (5) is given by

$$E_0 = \left(\frac{Z_H}{\mu_H} , 0 , 0 , 0 , \frac{Z_M}{[\mu_M + \beta u_2]} , 0 \right)$$

226

227 1.7 THE EFFECTIVE REPRODUCTION NUMBER R_e

228

229 The effective reproduction number is the basic reproduction number of the model with the
230 four controls (5). The basic reproduction number is defined as the expected number of
231 secondary infection cases produced by a single infectious individual in a completely susceptible
232 population. The next generation method is used to derived the basic reproduction number [23,
233 25].

234

235 The effective reproduction number is

$$R_e = \sqrt{\frac{\phi\Omega L_1 L_6 + \phi L_1 L_5 L_9 + \Omega L_2 L_6 L_7 + L_1 L_4 L_8 L_9 + L_2 L_5 L_7 L_9 + L_3 L_6 L_7 L_8}{L_7 L_8 L_9 L_{10}}}$$

where $L_1 = (1 - u_1)\Phi_I\theta_{MH}$, $L_2 = (1 - u_1)\Phi_A\theta_{MH}$, $L_3 = (1 - u_1)\Phi_P\theta_{MH}$,

$$L_4 = \frac{(1 - u_1)\Phi_I\theta_{HM}\mu_H Z_M}{[\mu_M + \beta u_2]Z_H}, \quad L_5 = \frac{(1 - u_1)\Phi_A\theta_{HM}\mu_H Z_M}{[\mu_M + \beta u_2]Z_H}, \quad L_6 = \frac{(1 - u_1)\Phi_P\theta_{HM}\mu_H Z_M}{[\mu_M + \beta u_2]Z_H}$$


236 , $L_7 = (A_1 + u_3 + u_6\Lambda_I)$, $L_8 = (A_2 + u_4 + u_7\Lambda_A)$, $L_9 = (A_3 + u_5 + u_8\Lambda_P)$ and

$$L_{10} = [\mu_M + \beta u_2],$$

237 1.8 THE IMPACT OF THE CONTROL STRATEGIES ON THE EFFECTIVE 238 REPRODUCTION NUMBER

239

240 The effective reproduction number is plotted against the four (4) control strategies in order to
241 show graphically the impact of the controls.



242

243 In fig. 3, it can be seen that as each control approaches one (1), the value of R_e decreases
 244 which means the controls have positive impact on the model. The use of ITNs (u_1) can
 245 even reduce the value of R_e to zero at $u_1 = 1$, which makes it the most effective control on
 246 R_e . The next effective control is the use of IRS (u_2), which can reduce the value of R_e
 247 to approximately 0.1 at $u_2 = 1$. Chemoprophylaxis (u_C) also has positive impact on the
 248 value of R_e , as it can decrease R_e to approximately 1 at $u_C = 1$. And finally, the use of
 249 Treatment effort. (u_T) can reduce the value of R_e to approximately 1.68 at $u_T = 1$.
 250 Therefore, all the control strategies have positive impact on the effective reproduction number
 251 as shown in fig. 3 above.

252

253 1.9 OBJECTIVE FUNCTION

254 The goal is to minimise the infected human and female Anopheles mosquito populations while
 255 maximizing the susceptible human population. The control functions are practised in the time
 256 interval $[0, T]$. Therefore, we can define the objective function as

$$J[\mathbf{u}_1, \mathbf{u}_2, \mathbf{u}_3, \mathbf{u}_4, \mathbf{u}_5, \mathbf{u}_6, \mathbf{u}_7, \mathbf{u}_8] = \int_0^T \left[D_1 + \frac{1}{2} D_2 \right] dt \quad \dots \dots (9)$$

where $D_1 = Y_1 I_I + Y_2 I_A + Y_3 I_P + Y_4 N_M$ and

$$D_2 = Z_1 u_1^2 + Z_2 u_2^2 + Z_3 u_3^2 + Z_4 u_4^2 + Z_5 u_5^2 + Z_6 u_6^2 + Z_7 u_7^2 + Z_8 u_8^2$$

257 The infectious people under 5years (I_I), infectious people over 5years (I_A), infectious
 258 pregnant women (I_P) and the total female Anopheles mosquito ($N_M = S_M + I_M$)
 259 populations are included in the objective function, because we want to minimise these
 260 populations. The terms Y_1, Y_2, Y_3 and Y_4 are positive weights to balance the factors
 261 of I_I, I_A, I_P and N_M , while $Z_1, Z_2, Z_3, Z_4, Z_5, Z_6, Z_7$ and Z_8 are also positive
 262 weights constants which measure the relative costs of implementing the respective
 263 strategies. The term $\frac{1}{2} Z_1 u_1^2$ represents the cost of implementing ITNs, $\frac{1}{2} Z_2 u_2^2$ also
 264 represents the cost of implementing indoor residual spraying (IRS),
 265 $\frac{1}{2} (Z_3 u_3^2 + Z_4 u_4^2 + Z_5 u_5^2)$ represent the cost of implementing of Chemoprophylaxis and
 266 finally, $\frac{1}{2} (Z_6 u_6^2 + Z_7 u_7^2 + Z_8 u_8^2)$ represents the cost of implementing of Improved clinical
 267 treatment (improved Antimalarial drugs).

268
 269 We seek an optimal control $u_1^*(t), u_2^*(t), u_3^*(t), u_4^*(t), u_5^*(t), u_6^*(t), u_7^*(t)$ and $u_8^*(t)$
 270 such that [12]

$$J(u_1^*, u_2^*, u_3^*, u_4^*, u_5^*, u_6^*, u_7^*, u_8^*) = \min_{W_1 \in U} \{ J(W_1) \mid W_1 \in U \},$$

where $W_1 = u_1, u_2, u_3, u_4, u_5, u_6, u_7, u_8$

271 U is the control set.

272 The control set U is defined as

$$U = \{ u_i \text{ is lebesgue measurable, } 0 \leq u_i \leq 1, i = 1, \dots, 8, \text{ for } t \in [0, T] \rightarrow [0, 1] \}.$$

273 The Lagrangian for the control problem is defined as

$$L = D_1 + \frac{1}{2} D_2$$

274 The necessary conditions that an optimal control must satisfy come from the Pontryagin
 275 Maximum Principle [9]. This principle converts (5) and (9) into a problem of
 276 minimising pointwise a Hamiltonian H , with respect to W_1

$$H = L + \lambda_{S_H} \frac{dS_H}{dt} + \lambda_{I_I} \frac{dI_I}{dt} + \lambda_{I_A} \frac{dI_A}{dt} + \lambda_{I_P} \frac{dI_P}{dt} + \lambda_{S_M} \frac{dS_M}{dt} + \lambda_{I_M} \frac{dI_M}{dt} \quad \dots \dots \dots (10)$$

$$\begin{aligned}
& Y_1 I_I + Y_2 I_A + Y_3 I_P + Y_4 N_M + \\
& \frac{1}{2} (Z_1 u_1^2 + Z_2 u_2^2 + Z_3 u_3^2 + Z_4 u_4^2 + Z_5 u_5^2 + Z_6 u_6^2 + Z_7 u_7^2 + Z_8 u_8^2) + \\
& \left. \begin{aligned}
& \lambda_{S_H} \left[Z_H + ((1 + u_6)\Lambda_I + u_3)I_I + ((1 + u_7)\Lambda_A + u_4)I_A + \right. \\
& \left. ((1 + u_8)\Lambda_P + u_5)I_P - \frac{(\Phi_I + \Phi_A + \Phi_P)(\mathbf{1} - \mathbf{u}_1)\theta_{MH}I_M S_H}{N_H} - \mu_H S_H \right] \\
& + \lambda_{I_I} \left[\frac{(\mathbf{1} - \mathbf{u}_1)\Phi_I \theta_{MH} I_M S_H}{N_H} - (A_1 + u_3 + u_6 \Lambda_I)I_I \right] + \lambda_{I_A} \left[\frac{(\mathbf{1} - \mathbf{u}_1)\Phi_A \theta_{MH} I_M S_H}{N_H} + \right. \\
& \left. \phi I_I - (A_2 + u_4 + u_7 \Lambda_A)I_A \right] + \\
& \lambda_{I_P} \left[\frac{(\mathbf{1} - \mathbf{u}_1)\Phi_P \theta_{MH} I_M S_H}{N_H} + \right. \\
& \left. \Omega I_A - (A_3 + u_5 + u_8 \Lambda_P)I_P \right] + \lambda_{S_M} \left[\frac{Z_M - [\mu_M + \beta u_2]S_M -}{N_H} \right. \\
& \left. \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(\mathbf{1} - \mathbf{u}_1)\theta_{HM} S_M}{N_H} \right] \\
& + \lambda_{I_M} \left[\frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(\mathbf{1} - \mathbf{u}_1)\theta_{HM} S_M}{N_H} - [\mu_M + \beta u_2]I_M \right]
\end{aligned} \right\}
\end{aligned}$$

277 where the λ_{S_H} , λ_{I_I} , λ_{I_A} , λ_{I_P} , λ_{S_M} , λ_{I_M} are the adjoint variables or co-state
278 variables. ([2, 26], Corollary 4. 1) gives the existence of optimal control due to the convexity of
279 the integrand of J with respect to $u_1, u_2, u_3, u_4, u_5, u_6, u_7$ and u_8 , a priori
280 boundedness of the state solutions, and the Lipschitz property of the state system with respect to
281 the state variables. Applying Pontryagin's Maximum Principle [27] and the existence result for
282 the optimal control from [26], we obtain the following theorem.

283 Theorem 1

284 Given an optimal control $u_1^*, u_2^*, u_3^*, u_4^*, u_5^*, u_6^*, u_7^*, u_8^*$ and $S_H^*, I_I^*, I_A^*, I_P^*,$
285 S_M^*, I_M^* of the corresponding state system (5) that minimises
286 $J(u_1, u_2, u_3, u_4, u_5, u_6, u_7, u_8)$ over U . Then there exists adjoint variables
287 $\lambda_{S_H}, \lambda_{I_I}, \lambda_{I_A}, \lambda_{I_P}, \lambda_{S_M}, \lambda_{I_M}$ satisfying

$$\left. \begin{aligned}
& \lambda_{S_H} \left[\frac{(\Phi_I + \Phi_A + \Phi_P)(\mathbf{1} - \mathbf{u}_1)\theta_{MH}I_M}{N_H} \left(1 - \frac{S_H}{N_H}\right) + \mu_H \right] \\
\frac{d\lambda_{S_H}}{dt} = & - \frac{(\mathbf{1} - \mathbf{u}_1)\theta_{MH}I_M}{N_H} \left(1 - \frac{S_H}{N_H}\right) [\Phi_I \lambda_{I_I} + \Phi_A \lambda_{I_A} + \Phi_P \lambda_{I_P}] \\
& + \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(\mathbf{1} - \mathbf{u}_1)\theta_{HM} S_M (\lambda_{I_M} - \lambda_{S_M})}{N_H^2}
\end{aligned} \right\} \dots (11)$$

$$\frac{d\lambda_{I_I}}{dt} = \frac{-[Y_1 + \lambda_{S_H}((1 + u_6)\Lambda_I + u_3) + \lambda_{I_A}\phi] + \lambda_{I_I}(A_1 + u_3 + u_6\Lambda_I) + (1 - \mathbf{u}_1)\theta_{MH}I_M S_H [\Phi_I(\lambda_{I_I} - \lambda_{S_H}) + \Phi_A(\lambda_{I_A} - \lambda_{S_H}) + \Phi_P(\lambda_{I_P} - \lambda_{S_H})]}{N_H^2} + \frac{(1 - \mathbf{u}_1)\theta_{HM}S_M(\lambda_{S_M} - \lambda_{I_M})}{N_H} \left[\Phi_I - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)}{N_H} \right] \quad \dots (12)$$

288

$$\frac{d\lambda_{I_A}}{dt} = \frac{-[Y_2 + \lambda_{S_H}((1 + u_7)\Lambda_A + u_4) + \lambda_{I_P}\Omega] + \lambda_{I_A}(A_2 + u_4 + u_7\Lambda_A) + (1 - \mathbf{u}_1)\theta_{MH}I_M S_H [\Phi_I(\lambda_{I_I} - \lambda_{S_H}) + \Phi_A(\lambda_{I_A} - \lambda_{S_H}) + \Phi_P(\lambda_{I_P} - \lambda_{S_H})]}{N_H^2} + \frac{(1 - \mathbf{u}_1)\theta_{HM}S_M(\lambda_{S_M} - \lambda_{I_M})}{N_H} \left[\Phi_A - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)}{N_H^2} \right] \quad \dots (13)$$

$$\frac{d\lambda_{I_P}}{dt} = \frac{-[Y_3 + \lambda_{S_H}((1 + u_8)\Lambda_P + u_5)] + \lambda_{I_P}(A_3 + u_5 + u_8\Lambda_P) + (1 - \mathbf{u}_1)\theta_{MH}I_M S_H [\Phi_I(\lambda_{I_I} - \lambda_{S_H}) + \Phi_A(\lambda_{I_A} - \lambda_{S_H}) + \Phi_P(\lambda_{I_P} - \lambda_{S_H})]}{N_H^2} + \frac{(1 - \mathbf{u}_1)\theta_{HM}S_M(\lambda_{S_M} - \lambda_{I_M})}{N_H} \left[\Phi_P - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)}{N_H^2} \right] \quad \dots (14)$$

$$\frac{d\lambda_{S_M}}{dt} = \frac{-Y_4 + \lambda_{S_M} \left[\frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(1 - \mathbf{u}_1)\theta_{HM}}{N_H} + [\mu_M + \beta u_2] \right]}{N_H} - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)(1 - \mathbf{u}_1)\theta_{HM}\lambda_{I_M}}{N_H} \quad \dots (15)$$

$$\frac{d\lambda_{I_M}}{dt} = \frac{-Y_4 + \lambda_{S_H} \left[\frac{(\Phi_I + \Phi_A + \Phi_P)(1 - \mathbf{u}_1)\theta_{MH}S_H}{N_H} \right]}{N_H} - \frac{(1 - \mathbf{u}_1)\theta_{MH}S_H [\Phi_I \lambda_{I_I} + \Phi_A \lambda_{I_A} + \Phi_P \lambda_{I_P}]}{N_H} + \lambda_{I_M} [\mu_M + \beta u_2] \quad \dots (16)$$

289

290 The above adjoint equations [6] (11) - (16) satisfy transversality conditions

$$\lambda_{S_H}(T) = \lambda_{I_I}(T) = \lambda_{I_A}(T) = \lambda_{I_P}(T) = \lambda_{S_M}(T) = \lambda_{I_M}(T) = 0 \quad \dots \dots \dots (17)$$

291 and the controls $u_1^*, u_2^*, u_3^*, u_4^*, u_5^*, u_6^*, u_7^*$ and u_8^* satisfy the optimality
 292 condition

$$\left. \begin{aligned} u_1^* &= \max \left\{ 0, \min \left(1, \frac{1}{Z_1 N_H} (\theta_{MH} I_M^* S_H^* D_3 + D_4) \right) \right\} \\ u_2^* &= \max \left\{ 0, \min \left(1, \frac{\beta}{Z_2} (\lambda_{S_M} S_M^* + \lambda_{I_M} I_M^*) \right) \right\} \\ u_3^* &= \max \left\{ 0, \min \left(1, \frac{I_I^*}{Z_3} (\lambda_{I_I} - \lambda_{S_H}) \right) \right\} \\ u_4^* &= \max \left\{ 0, \min \left(1, \frac{I_A^*}{Z_4} (\lambda_{I_A} - \lambda_{S_H}) \right) \right\} \\ u_5^* &= \max \left\{ 0, \min \left(1, \frac{I_P^*}{Z_5} (\lambda_{I_P} - \lambda_{S_H}) \right) \right\} \\ u_6^* &= \max \left\{ 0, \min \left(1, \frac{\Lambda_I I_I^*}{Z_6} (\lambda_{I_I} - \lambda_{S_H}) \right) \right\} \\ u_7^* &= \max \left\{ 0, \min \left(1, \frac{\Lambda_A I_A^*}{Z_7} (\lambda_{I_A} - \lambda_{S_H}) \right) \right\} \\ u_8^* &= \max \left\{ 0, \min \left(1, \frac{\Lambda_P I_P^*}{Z_8} (\lambda_{I_P} - \lambda_{S_H}) \right) \right\} \end{aligned} \right\} \dots \dots \dots (18)$$

where $D_3 = \Phi_I (\lambda_{I_I} - \lambda_{S_H}) + \Phi_A (\lambda_{I_A} - \lambda_{S_H}) + \Phi_P (\lambda_{I_P} - \lambda_{S_H})$ and
 $D_4 = (\Phi_I I_I^* + \Phi_A I_A^* + \Phi_P I_P^*) \theta_{HM} S_M^* (\lambda_{S_M} + \lambda_{I_M})$.

293 Proof

294 We can obtain u_1^* as follows:

$$\frac{\partial H}{\partial u_1} = \left[\begin{aligned} & Z_1 u_1 + \frac{(\Phi_I + \Phi_A + \Phi_P) \theta_{MH} I_M^* S_H^* \lambda_{S_H}}{N_H} \\ & - \frac{\Phi_I \theta_{MH} I_M^* S_H^* \lambda_{I_I}}{N_H} - \frac{\Phi_A \theta_{MH} I_M^* S_H^* \lambda_{I_A}}{N_H} \\ & - \frac{\Phi_P \theta_{MH} I_M^* S_H^* \lambda_{I_P}}{N_H} \\ & - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P) \theta_{HM} S_M^* \lambda_{S_M}}{N_H} \\ & - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P) \theta_{HM} S_M^* \lambda_{I_M}}{N_H} \end{aligned} \right] = 0$$

295

$$\Rightarrow \left[\begin{array}{c} Z_1 \mathbf{u}_1 + \frac{(\Phi_I + \Phi_A + \Phi_P)\theta_{MH}I_M^*S_H^* \lambda_{S_H}}{N_H} \\ - \frac{\Phi_I\theta_{MH}I_M^*S_H^*\lambda_{I_I}}{N_H} - \frac{\Phi_A\theta_{MH}I_M^*S_H^*\lambda_{I_A}}{N_H} \\ - \frac{\Phi_P\theta_{MH}I_M^*S_H^*\lambda_{I_P}}{N_H} \\ - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M \lambda_{S_M}}{N_H} \\ - \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M \lambda_{I_M}}{N_H} \end{array} \right] = 0$$

$$\Rightarrow Z_1 \mathbf{u}_1 = \begin{array}{c} - \frac{(\Phi_I + \Phi_A + \Phi_P)\theta_{MH}I_M^*S_H^* \lambda_{S_H}}{N_H} \\ + \frac{\Phi_I\theta_{MH}I_M^*S_H^*\lambda_{I_I}}{N_H} + \frac{\Phi_A\theta_{MH}I_M^*S_H^*\lambda_{I_A}}{N_H} \\ + \frac{\Phi_P\theta_{MH}I_M^*S_H^*\lambda_{I_P}}{N_H} \\ + \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M \lambda_{S_M}}{N_H} \\ + \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M \lambda_{I_M}}{N_H} \end{array}$$

$$\Rightarrow Z_1 \mathbf{u}_1 = \begin{array}{c} \frac{\Phi_I\theta_{MH}I_M^*S_H^*(\lambda_{I_I} - \lambda_{S_H})}{N_H} + \frac{\Phi_A\theta_{MH}I_M^*S_H^*(\lambda_{I_A} - \lambda_{S_H})}{N_H} \\ + \frac{\Phi_P\theta_{MH}I_M^*S_H^*(\lambda_{I_P} - \lambda_{S_H})}{N_H} \end{array}$$

$$\Rightarrow Z_1 \mathbf{u}_1 = \begin{array}{c} \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M (\lambda_{S_M} + \lambda_{I_M})}{N_H} \\ \frac{\theta_{MH}I_M^*S_H^*}{N_H} [\Phi_I(\lambda_{I_I} - \lambda_{S_H}) + \Phi_A(\lambda_{I_A} - \lambda_{S_H}) + \Phi_P(\lambda_{I_P} - \lambda_{S_H})] \\ \frac{(\Phi_I I_I + \Phi_A I_A + \Phi_P I_P)\theta_{HM}S_M (\lambda_{S_M} + \lambda_{I_M})}{N_H} \end{array}$$

Let $D_3 = \Phi_I(\lambda_{I_I} - \lambda_{S_H}) + \Phi_A(\lambda_{I_A} - \lambda_{S_H}) + \Phi_P(\lambda_{I_P} - \lambda_{S_H})$ and

$$D_4 = (\Phi_I I_I^* + \Phi_A I_A^* + \Phi_P I_P^*)\theta_{HM}S_M^* (\lambda_{S_M} + \lambda_{I_M}) .$$

$$\Rightarrow \mathbf{u}_1 = \frac{1}{Z_1} \left[\frac{\theta_{MH} I_M^* S_H^*}{N_H} [D_3] + \frac{D_4}{N_H} \right] = \frac{1}{Z_1 N_H} (\theta_{MH} I_M^* S_H^* D_3 + D_4)$$

$$u_1^* = \frac{1}{Z_1 N_H} (\theta_{MH} I_M^* S_H^* D_3 + D_4)$$

296 Similarly, the remaining control policies can be obtained by this method.

297 The next thing to consider is the numerical solutions of the optimality system.

298 1.10 NUMERICAL RESULTS

299 Numerical solution to the optimality system is obtained by solving optimality system using an
 300 iterative scheme. The solution process involves using an initial guess of the controls to solve the
 301 state equations with forward scheme. The resulting solution of the state equation together with
 302 guessed controls are used to solve the co-state equation with a backward scheme due to the
 303 nature of the transversality conditions, which are final time conditions. The controls are updated
 304 using a convex combination of their previous values and the values from the characterizations.
 305 This process is continued until the unknowns at the present iteration are sufficiently close to
 306 those in the previous one [6, 11, 28].

307 The following weights factors $\mathbf{Y}_1 = 1000$, $\mathbf{Y}_2 = 600$, $\mathbf{Y}_3 = 800$ and $\mathbf{Y}_4 = 200$ are
 308 used for the numerical simulations. The cost associated with \mathbf{u}_1 includes purchasing bed-net
 309 and insecticide chemicals for treating the bed-net and the cost associated with \mathbf{u}_2 will include
 310 the cost of buying insecticide chemical and labour cost of spraying. The cost associated with
 311 chemoprophylaxis (\mathbf{u}_3 , \mathbf{u}_4 and \mathbf{u}_5) is the cost of buying the drugs for the whole year.
 312 And finally, the cost associated with clinical treatment (\mathbf{u}_6 , \mathbf{u}_7 and \mathbf{u}_8) includes the cost
 313 of antimalarial drugs., pain relief drugs, laboratory test cost and medical consultation fee.
 314 Therefore, we have $\mathbf{Z}_1 = \$6.00$, $\mathbf{Z}_2 = \$14.40$, $\mathbf{Z}_3 = \$196.4$, $\mathbf{Z}_4 = \$312$, $\mathbf{Z}_5 = \$1.67$,
 315 $\mathbf{Z}_6 = \$28.93$, $\mathbf{Z}_7 = \$19.28$ and $\mathbf{Z}_8 = \$24.10$. The parameter $\beta = 0.00003$

316
 317 We begin by plotting the single controls, that is, plotting ITN only, IRS only, Chemoprophylaxis
 318 only and Clinical treatment only, in order to compare the impact of each control.

319
 320
 321
 322




Figure 4: Plots of model without control, ITN only, IRS only, Chemoprophylaxis only and Clinical treatment only.

323

324 From fig. 4, it can be seen that Chemoprophylaxis u_C (u_3 , u_4 , u_5) only as a single control
 325 has greatest impact on malaria prevention, that is, it can prevent approximately a total of
 326 **88,097,000** malaria infection cases in humans. It is followed by ITN (u_1) only which can
 327 also prevent **86,878,000** malaria infection cases. An improvement in Clinical treatment
 328 u_T (u_6 , u_7 , u_8) effort only can prevent **65,746,000** malaria infection cases. The
 329 control strategy with least malaria prevention is IRS only which can prevent **60,935,000**.

330

331 Therefore, we now move on to compare the impact of combining two control strategies such as
 332 ITN and IRS, ITN and Chemoprophylaxis, ITN and Clinical treatment, IRS and
 333 Chemoprophylaxis, IRS and Clinical treatment and Chemoprophylaxis and Clinical treatment.
 334 Their plots are given in fig. 5 and 6 below.

335




Figure 5: Plots of model without control, ITN and IRS, ITN and Chemoprophylaxis, ITN and Clinical treatment.

336




Figure 6: Plots of model without control, IRS and Chemoprophylaxis, IRS and Clinical treatment and Chemoprophylaxis and Clinical treatment.

337

338 From fig. 5 and 6, the combination with the highest malaria prevention cases is ITN and
 339 Chemoprophylaxis, it can prevent a total of **95,022,000** malaria infection cases in humans. It
 340 is followed by the combination of ITN and Treatment which can prevent **90,192,000** malaria
 341 infection cases. The combination of Chemoprophylaxis and Treatment can prevent
 342 **88,943,000** malaria infection cases. This is also followed by the combination of IRS and
 343 Chemoprophylaxis which can prevent **88,097,000** malaria infection cases. We also have the
 344 combination of ITN and IRS which can prevent **86,878,000** malaria infection cases. And
 345 finally, the combination of IRS and Treatment gives the least prevention, which is the sum total
 346 of **65,293,000** malaria infection cases.

347
 348 Next, we consider the combination of three control strategies such as ITN, IRS and
 349 Chemoprophylaxis; ITN, IRS and Clinical treatment; ITN, Chemoprophylaxis and Clinical
 350 treatment and IRS, Chemoprophylaxis and Clinical treatment.




Figure 7: Plots of model without control, ITN, IRS and Chemoprophylaxis; ITN, IRS and Clinical treatment; ITN, Chemoprophylaxis and Clinical treatment and IRS, Chemoprophylaxis and Clinical treatment

351
 352 From figure 7, it can be seen that the combination of ITN, Chemoprophylaxis and Treatment
 353 improvement effort recorded the highest malarial prevention among the categories of the
 354 combining three control strategies. This combination can prevent a total of **95,237,000**
 355 malaria infection cases. This is followed by the combination of ITN, IRS and
 356 Chemoprophylaxis which can prevent **95,022,000** malaria infection cases. The combination
 357 of ITN, IRS and Treatment can also prevent **90,192,000** malaria infection cases. The
 358 combination of IRS, Chemoprophylaxis and Treatment gives the least malaria prevention in this
 359 category, which is **88,943,000** malaria infection cases.

360 Finally, we now consider the impact of combining all four control strategies on the optimality
 361 system.
 362




Figure 8: Plots of model without control and the combination of all four control strategies on the model.

363
 364 From figure 8, the combination of all four control strategies can prevent approximately a total of
 365 **95,237,000** malaria infections cases in humans which is the same as the result produced by
 366 combining ITN, Chemoprophylaxis and Treatment in fig. 7.

367
 368 It can be seen that in fig. 4, Chemoprophylaxis only recorded highest malaria prevention as a
 369 single control in the optimality system. It produces the same result as combining IRS and
 370 Chemoprophylaxis in fig. 6 and produced a better result than the results produced by the
 371 combinations of ITN and IRS, and IRS and Treatment in figures. 5 and 6 respectively. ITN only
 372 as single control on the system in fig. 4 produces the same result as the result recorded by the
 373 combination of ITN and IRS in fig. 5 and better than the result produced by IRS and
 374 Treatment in fig. 6. The result produced by the combination of ITN and Chemoprophylaxis in
 375 fig. 5 is the same as the result produced by ITN, IRS and Chemoprophylaxis in fig. 7 and
 376 better than the results recorded by the combinations of ITN, IRS and Treatment and IRS,
 377 Chemoprophylaxis and Treatment in fig 7. It is not enough to use only graphs to determine the
 378 most efficient strategy, therefore, we employ a quantitative methodology such as cost
 379 effectiveness analysis to do that [28].

380 381 1.11 COST EFFECTIVENESS ANALYSIS

382 The CEA is a type of economic evaluation which compares the costs and outcomes of health
 383 programs when the interventions have a common health outcome but differ in effectiveness. In
 384 order to assess the extent to which our control intervention strategies are beneficial and cost

385 effective, we employ the incremental cost-effectiveness ratio (ICER). The ICER is often defined
 386 as the additional cost per additional health outcome and provides a means of comparing
 387 intervention strategies so that we are able to determine which strategy is most cost-effective
 388 control in disease eradications.
 389 Mathematically, the ICER between two strategies is defined in this work as:
 390

$$\text{ICER} = \frac{\text{Differences in cost of interventions strategies}}{\text{Differences in number of infection averted by the strategies}} \dots\dots (19)$$

391 The basic assumption in using the ICER is based on the understanding that the
 392 prime goal of using ITN, IRS, Chemoprophylaxis and an Improvement of the current
 393 Treatment is to reduce malaria infection. In order to use the ICER, we are required to rank
 394 all the intervention strategies according to their effectiveness on the basis of
 395 securing maximum effect rather than considering cost [1, 7].
 396

397 Based on the model simulation results, the strategies worth ranking in term of
 398 cost-effectiveness are stated in the table 3 below:

399 Table 3: Ranking of the intervention strategies

Strategies	Total infection averted	Cost (\$)
No strategy	0	0
IRS only	60,935,000	877,470.000
Treatment only	65,746,000	1,470,900,000
ITN only	86,878,000	417,020.000
Chemoprophylaxis only	88,097,000	23,854,000,000
ITN and Treatment	90,192,000	1,530,050,000

400

401 The ICER, is computed as follows:

$$\text{ICER(IRS only)} = \frac{877,470.000 - 0}{60,935,000 - 0} = \frac{877,470.000}{60,935,000} = 14.4$$

$$\text{ICER(Treatment only)} = \frac{1,470,900,000 - 877,470.000}{65,746,000 - 60,935,000} = \frac{593,430,000}{4,811,000} = 123.35$$

402 Comparing ICER(IRS only) and ICER(Treatment only) , it can be seen that there is a cost of
 403 \$14.4 for strategy IRS only over strategy Treatment only . The lower ICER for strategy
 404 IRS only shows that strategy Treatment only is strongly dominated. This makes strategy
 405 Treatment only more costly and less effective than strategy IRS only . Hence, strategy
 406 Treatment only is excluded from the from the set of alternatives so it does not consume limited
 407 resources. This leads to table 4

408

409 Table 4: Ranking of IRS only, ITN only, Chemoprophylaxis only and ITN and Treatment
 410 combination strategies

Strategies	Total infection averted	Cost (\$)
IRS only	60,935,000	877,470.000
ITN only	86,878,000	417,020.000
Chemoprophylaxis only	88,097,000	23,854,000,000
ITN and Treatment	90,192,000	1,530,050,000

411

412 We recalculate ICER,

$$\text{CER(IRS only)} = \frac{877,470.000}{60,935,000} = 14.4$$

$$\text{ICER(ITN only)} = \frac{417,020.000 - 877,470.000}{88,943,000 - 60,935,000} = \frac{-460,450,000}{27,162,000} = -16.95$$

413 Again, comparing CER(IRS only) and ICER(ITN only), we have a cost saving of \$16.95 for
 414 strategy ITN only over IRS only. The negative ICER for strategy ITN only shows that
 415 strategy IRS only is strongly dominated. Therefore, strategy IRS only is excluded and this
 416 leads to table 5.

417 Table 5: Ranking of ITN only, Chemoprophylaxis only and ITN and Treatment
 418 combination strategies

Strategies	Total infection averted	Cost (\$)
ITN only	86,878,000	417,020.000
Chemoprophylaxis only	88,097,000	23,854,000,000
ITN and Treatment	90,192,000	1,530,050,000

419

420 We recalculate ICER,

$$\text{ICER(ITN only)} = \frac{417,020.000}{86,878,000} = 4.8$$

$$\text{ICER(Chemoprophylaxis only)} = \frac{23,854,000,000 - 417,020.000}{88,097,000 - 86,878,000} = \frac{23,436,980,000}{1219000} = 19226.4$$

421 Hence, strategy Chemoprophylaxis only is excluded from the from the set of alternatives so it
 422 does not consume limited resources. This leads to table 6.

423

424 **Table 6: Ranking of ITN only and ITN and Treatment combination strategies**

Strategies	Total infection averted	Cost (\$)
ITN only	86,878,000	417,020.000
ITN and Treatment	90,192,000	1,530,050,000

425

426 We recalculate ICER,

$$\text{ICER(ITN only)} = \frac{417,020.000}{86,878,000} = 4.8$$

$$\begin{aligned} \text{ICER(ITN and Treatment)} &= \frac{1,530,050,000 - 417,020.000}{90,192,000 - 86,878,000} = \frac{1,113,030,000}{3314000} \\ &= 335.86 \end{aligned}$$

427 Hence, strategy ITN and Treatment is excluded from the from the set of alternatives so it does
428 not consume limited resources. This leads to table 7

429 **Table 7: ITN strategy only**

Strategies	Total infection averted	Cost (\$)
ITN only	86,878,000	417,020.000

430

431 Therefore, it can be seen that the strategy ITN only is best for controlling malaria in terms of
432 cost. Therefore, I will recommend that policy makers on Malaria Control Programmes in
433 endemic areas should advise their governments to subsidy ITN for its citizens or make it free and
434 compulsory. However, this does not mean other strategies are not necessary, it is only telling us
435 that more attention should be given to ITN. Although, the other strategies such as
436 Chemoprophylaxis, IRS and Improved Treatment are good to avert malaria infections as seen in
437 figures 4 to 8. However, their costs do not make them economically viable to assist malaria
438 victims. For example, Chemoprophylaxis for those over 5years is about Twenty-Seven Ghana
439 Cedis (6 US dollars) per week and for pregnant women it is free when they visit Anti-neonatal
440 clinic and Seven Ghana Cedis and Fifty Pesewas (1.67 US dollars) at a Pharmaceutical shop in
441 Ghana for a dosage during a pregnancy in the year 2018. Therefore, only privileged few of the
442 malaria victims can afford it and also it is recommended for a short time and not for our whole
443 life time.

444 Therefore, as the Cost-effectiveness Analysis points out in this work that ITN is economically
445 best solution for fighting malaria in poor endemic areas, I will recommend that more attention
446 should be given to the ITN; because personally I used one ITN for most three years at Navrongo
447 in the Upper East region of Ghana which I received for free during a Malaria Control
448 Programme.

449 **1.12 CONCLUSION**

450 In this article, we apply the optimal control theory to a new model formulated for malaria disease
451 in endemic areas in the world. The following malaria control strategies ITN, IRS,
452 Chemoprophylaxis and Improved Clinical Treatment were examined and analysed on the mode.
453 The Cost-effectiveness Analysis points out that more attention should be given Insecticide -
454 Treated bed nets (ITNs) in order to eliminate the malaria disease globally, because the female
455 Anopheles mosquitoes need human blood to lay their eggs [10]. The expression for the effective
456 reproduction number (R_e) has been derived by using the next-generation method. The impact
457 of the controls on the R_e was studied and it came out that all four controls have positive impact.
458 The epidemiological theory states if R_e is less than one, then the disease can easily be
459 eliminated. An analysis of controls on R_e reveals that the ITNs can reduce R_e to zero as the
460 value of ITNs approaches one. Pontryagin's Maximum Principle is applied to analyse the
461 optimal control model theoretically and the optimality system is solved numerically through an
462 iterative scheme. The optimal plots (Fig.4-8) reveal that best control strategies for malaria
463 elimination is the combination of ITN, Chemoprophylaxis and Improved Clinical Treatment.
464 However, the Cost-effectiveness Analysis points out in this article that ITN is economically best
465 solution for fighting malaria in poor endemic areas.

466 **REFERENCE**

- 467 [1] P.M. M. Mwamtobe (2014): PhD Thesis- Optimal (Control of) Intervention Strategies
468 for
469 Malaria Epidemic in Karonga District, Malawi. School of Computational and Applied
470 Mathematics, University of the Witwatersrand, Johannesburg, South Africa.
471
- 472 [2] K. Blayneh, Y. Cao and H-D. Kwon (2009): Optimal Control of Vector-Borne Diseases:
473 Treatment and Prevention. Discrete and Continuous Dynamical Systems Series B, Volume
474 11, Number 3, May 2009, [doi:10.3934/dcdsb.2009](https://doi.org/10.3934/dcdsb.2009). pp. 11-. xx.
475
- 476 [3] K. O. Okosun, O. Rachid, and N. Marcus (2011). Optimal control analysis of a malaria
477 disease transmission model that includes treatment and vaccination with waning
478 immunity. BioSystems, 106, 136 - 145.
479
- 480 [4] E. Hansen (2011): PhD Thesis- Applications of Optimal Control Theory to Infectious
481 Disease Modeling. Queen's University Kingston, Ontario, Canada
482
- 483 [5] G. Otieno, J.K. Koske and J. M. Mutiso (2016): Transmission Dynamics and Optimal
484 Control of Malaria in Kenya. Hindawi Publishing Corporation, Discrete Dynamics in
485 Nature and Society, Volume 2016, Article ID 8013574, 27 pages,
486 <http://dx.doi.org/10.1155/2016/8013574>.
487
- 488 [6] L. M. Neilan and S. Lenhart (2010): An Introduction to Optimal Control with an
489 Application in Disease Modeling. DIMACS Series in Discrete Mathematics and

- 490 Theoretical Computer Science, Volume 75, 2010
491
- 492 [7] K. O. Okosun, O. Rachid, and N. Marcus (2013). Optimal control strategies and
493 cost-effectiveness analysis of a malaria model BioSystems, 111(2013)83-101.
494 journal home page: www.elsevier.com/locate/biosystems
495
- 496 [8] H. S. F. Rodrigues (2012): PhD Thesis- Optimal Control and Numerical Optimization
497 Applied to Epidemiological Models. Department of Mathematics, University of Aveiro.
498
- 499 [9] S. F. Sadiq, M. A. Khan, S. Islam, G. Zaman, II Hyo Jung and S. A. Khan (2014):
500 Optimal
501 Control of an Epidemic Model of Leptospirosis with Nonlinear Saturated Incidences.
502 Annual Research and Review in Biology 4(3): 560-576, 2014. SCIENCEDOMAIN
503 international. www.sciencedomain.org.
504
- 505 [10] R. J. Patinvoh and A. A. Susu (2014): Mathematical Modelling of Sterile Insect
506 Technology
507 for Mosquito Control. Advances in Entomology, 2, 180-193.
508 <http://dx.doi.org/10.4236/ae.2014.24027>.
509
- 510 [11] T. T. Yusuf and F. Benyah (2012): Optimal control of vaccination and treatment for an
511 SIR
512 epidemiological model. Department of Mathematics and Applied Mathematics, University
513 of the Western Cape, Bellville 7535, South Africa. ISSN 1 746-7233, England, UK. World
514 Journal of Modelling and Simulation, Vol. 8(2012) No. 3, pp. 194-204.
515
- 516 [12] M. El hia, O. Balatif, M. Rachik and J. Bouyaghroumni (2013): Application of optimal
517 control theory to an SEIR model with immigration of infectives. Laboratory of Analysis
518 Modeling and Simulation, Department of Mathematics and Computer Science, Faculty of
519 Sciences Ben M. Sik, University Hassan II Mohammedia, BP 7955, Sidi Othman,
520 Casablanca, Morocco. IJCSI International Journal of Computer Science Issues, Vol. 10,
521 Issue 2, No 2, March 2013 ISSN (Print): 1694-0814 | ISSN (Online): 1694-0784
522 www.IJCSI.org
523
- 524 [13] F. B. Augusto, N. Marcus and K. O. Okosun (2012): Application to Optimal Control to the
525 Epidemiology of Malaria. Electronic Journal of Differential Equations, Vol. 2012 (2012),
526 No. 81, pp. 1–22. ISSN: 1072-6691. URL: <http://ejde.math.txstate.edu> or
527 <http://ejde.math.unt.edu> ftp ejde.math.txstate.edu
528
- 529 [14]. B. N. Kim, K. Nah, C. Chu, S. U. Ryu, Y. H. Kang and Y. Kim (2012): Optimal
530 control strategy of Plasmodium vivax malaria transmission in Korea. Osong Public
531 Health and Research Perspectives, 3(3), 128 - 136.
532
- 533 [15]. O. D. Makinde, and K. O. Okosun (2011): Impact of chemo-therapy on the optimal
534 control of malaria disease with infected immigrants. BioSystems, 104, 32 - 41.
535

- 536 [16]. K. O. Okosun (2010): Mathematical epidemiology of Malaria disease transmission and
537 its optimal control analysis. (PhD thesis), University of the Western Cape, South Africa.
538
- 539 [17]. C. J. Silva and D. F. M. Torres (2013): An optimal control approach to malaria
540 prevention via insecticide-treated nets. Hindawi Publishing Corporation Conference
541 Papers in Mathematics, vol. 2013, Article ID 658468.
542
- 543 [18]. M. Rafikov, L. Bevilacqua and A. P. P. Wyse (2009): Optimal control strategy of
544 malaria vector using genetically modified mosquitoes. *Journal Theoretical Biology*, 258,
545 418 - 425.
546
- 547 [19]. G. Magombedze, C. Chiyaka and Z. Mukandavire (2011): Optimal control of malaria
548 chemotherapy. *Nonlinear Analysis: Modelling and Control*, 16(4), 415- 434.
549
- 550 [20]. S. Owusu-Agyei, T. Smith, H. P. Beck, L. Amengo-Etego and I. Felger (2002).
551 Molecular
552 epidemiology of Plasmodium falciparum infections among asymptomatic inhabitants of a
553 holoendemic malarious area in northern Ghana. Navrongo Health Research Centre,
554 Navrongo, Ghana. *Tropical Medicine and International Health*, Volume 7 No.5 pp. 421-
555 428 May 2002.
556
- 557 [21]. A. Ducrot, S. B. Sirima, B. Somé and P. Zongo (2009): “A mathematical model for
558 malaria
559 involving differential susceptibility, exposedness and infectivity of human host, *Journal*
560 *of Biological Dynamics*, 3:6, 574-598, <http://dx.doi.org/10.1080/17513750902829393>.
561
- 562 [22]. G. T. Azu-Tungmah (2012). MPhil-Thesis: A Mathematical model to control the spread
563 of
564 Malaria in Ghana. Department of Mathematics under College of Science, Kwame
565 Nkrumah
566 University of Science and Technology, Kumasi-Ghana.
567
- 568 [23]. J. M. Addawe and J. E. C. Lope (2012). Analysis of Aged-structured malaria transmission
569 model. Department of Mathematics and Computer Science, University of the Philippines
570 Baguio.
571
- 572 [24]. G. O. Lawi, J. Y. T. Mugisha and N. Omolo – Ongati (2011): Mathematical Model for
573 Malaria and Meningitis Co-infection among Children. *Applied Mathematical Sciences*,
574 Vol. 5, no. 47, 2337 – 2359.
575
- 576 [25]. J. Medlock (2010): Mathematical Analysis of Epidemiological Models. Computing R_0 .
577 Clemson University, Department of Mathematical Sciences.
578
- 579 [26] W.H. Fleming and R. W. Rishel (1975): *Deterministic and Stochastic Optimal Control*.
580 Springer Verlag, New York.
581

- 582 [27] L. S. Pontryagin, V. G. Boltyanskii, R. V. R.V. Gamkrelidze, E.F. Mishchenko (1962):
583 The mathematical theory of optimal processes, Wiley, New York.
584
- 585 [28] B. Seidu, O. D. Makinde and I. Y. Seini (2015): Mathematical Analysis of Effects of
586 HIV-Malaria Co-infection on Workplace Productivity. Spring Science Business Media
587 Dordrecht 2015, DOI 10.1007/s10441-015-9255-y.
588
- 589 [29] B. Pluess, F.C. Tanser, C. Lengeler and B. L. Sharp (2010): Indoor residual spraying for
590 preventing malaria. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.:
591 CD006657. DOI: 10.1002/14651858.CD006657.pub2. The Cochrane Collaboration.
592 Published by John Wiley & Sons, Ltd.
593
- 594 [30]. G. T. Azu-Tungmah, F. T. Oduro and G. A. Okyere (2017): Estimating the Parameters
595 of a Disease Model from Clinical Data. Journal of Advanced in Mathematics and
596 Computer Science. 24(3): 1-11, 2017; Article no. JAMCS.34641.
597
- 598 [31]. G. T. Azu-Tungmah, F. T. Oduro and G. A. Okyere (2019): Analysis of an Age-
599 Structured
600 Malaria Model Incorporating Infants and Pregnant Women. Journal of Advanced in
601 Mathematics and Computer Science. 30(4): 1-21, 2019; Article no. JAMCS.46649
602